Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people starting Wegovy assume it works like a course of antibiotics: take it for a set number of weeks, stop, and keep the results. That is not how semaglutide works. How long you will be on Wegovy depends on your health, how your body responds, and what your prescriber recommends — and for many people, that means treatment lasting well beyond a year. Wegovy (semaglutide) is a prescription-only medicine and every decision about duration is made by a clinician who knows your full picture, not a fixed calendar.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common misconception is that there is a standard course length, six months, a year, and you are done. It is understandable. Most medicines work that way. Wegovy does not.
Semaglutide acts on GLP-1 receptors to reduce appetite and slow gastric emptying. Those effects are present while you are taking it. When the drug clears your system, the appetite suppression goes with it. The body's drive to return to its previous weight is well documented in the clinical literature, which is exactly why the question of how long you stay on it matters so much.
The STEP 1 trial (68 weeks of treatment in adults with obesity) showed an average weight reduction of around 15% at the 2.4mg maintenance dose, a figure published in the New England Journal of Medicine. A follow-up study found that a year after stopping, participants had regained most of that weight. The trial data make the case clearly: results are tied to continued treatment, not a finite course.
That is not a failure of the medicine. It reflects the biology of obesity, a chronic condition, not a temporary one. Framing duration as "how long until I stop" often sets the wrong expectation from the start. The better question is what treatment looks like over time, and when it is right to step back.
On the NHS, the guidance is specific. NICE's appraisal of semaglutide for weight management, TA875, recommends it for a maximum of two years, within a specialist weight management service that includes multidisciplinary support. That two-year cap applies to NHS commissioning; it does not mean the medicine stops working or becomes unsafe at 24 months. It reflects how NICE assessed cost-effectiveness for the NHS at the point of publication.
There is also a clinical review built into the guidance: if someone has not lost at least 5% of their body weight after six months at the maintenance dose, the prescriber should consider stopping treatment. Progress is monitored, not assumed.
Private prescribing sits outside these NHS parameters. Duration is a clinical decision between you and your prescriber, informed by your response to treatment, your health goals, and your overall medical history. There is no automatic two-year cut-off in private practice, but equally, no clinician will keep renewing a prescription that is not working.
It is worth being honest about timelines, because this affects how people feel in the early weeks. The first pen at 0.25mg is a tolerability dose; its purpose is to let your body adjust, not to produce meaningful weight loss immediately. Titration through 0.5mg, 1mg, 1.7mg and finally 2.4mg takes roughly four to five months in most people, each step lasting around four weeks.
So by the time you are at the full maintenance dose and have had several weeks to feel its effect, you may already be four to six months in. When weight loss begins to feel significant varies; some people notice change in the first month, others need longer. The pace of loss is individual, shaped by starting weight, diet, activity, and how your body responds to semaglutide specifically.
If you are wondering how long Wegovy takes to work in practical terms, the honest answer is: give it the full titration period before drawing conclusions. Stopping early because the starter dose did not deliver immediate results is one of the most common reasons treatment underperforms.
Whatever duration you and your prescriber agree on, the period on treatment is preparation for what follows. The appetite reduction Wegovy produces is most valuable when it is used to build habits (regular meals, adequate protein, movement) that can persist independently. That is not optional. It is what determines whether a year or two on treatment translates into lasting change.
If you are curious about how long treatment can continue safely, or want a clearer sense of expected weight loss across a full treatment period, those are exactly the questions our prescribers work through with you. We know this is not a straightforward decision, and if you are sitting with uncertainty about whether to start or how to plan ahead, that is a reasonable place to be.
At nume, a real clinician reads every consultation the same day, not automated software, not a generic questionnaire output. Our clinical team reviews your full health picture before any prescription is issued, and before every repeat. Start your free consultation if you want to talk through what treatment could look like for you.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.